Procter & Gamble Health Limited (PGHL) has announced its unaudited financial results for the second quarter of the fiscal year 2025-26, ending September 30, 2025. The company has demonstrated strong performance with growth in both top-line and bottom-line figures.

Financial Highlights

*All figures in crores except for Earnings Per Share

Key Performance Indicators

• Sales Growth: PGHL reported sales of ₹319.00 crores, marking a 3% increase compared to the same quarter last year.
• Profit After Tax (PAT): The company's PAT stood at ₹89.00 crores, up by 8% year-over-year.
• Half-Year Performance: For the six-month period ended September 30, 2025, PGHL recorded a revenue of ₹109.30 crores with a net profit of ₹154.80 crores.
• Cash Position: Cash and cash equivalents increased to ₹279.30 crores as of September 30, 2025, from ₹182.30 crores as of March 31, 2025, indicating strong liquidity.

Strategic Initiatives

Mr. Milind Thatte, Managing Director of P&G Health India, attributed the sustained growth momentum to several strategic efforts:

1. Brand Communication: Strategic consumer communication initiatives for key brands like Evion and Seven Seas.
2. Product Innovation: Introduction of new products such as Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream.
3. Supply Chain Enhancement: Continued strengthening of supply chain capabilities to meet evolving consumer and healthcare professional needs.
4. Market Approach: Focus on superior brand building, go-to-market initiatives, and science-backed innovations.

Company Overview

Procter & Gamble Health Limited is a leading player in India's vitamins, minerals, and supplements (VMS) market. The company manufactures and markets VMS products for a healthy lifestyle and improved quality of life, with a portfolio including popular brands such as Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion.

Market Response

The financial results were approved by the PGHL Board of Directors at a meeting held on November 5, 2025. The company's performance reflects its strong market position and effective strategy execution in a competitive healthcare products landscape.

Conclusion

Procter & Gamble Health Limited's Q2 FY2026 results demonstrate the company's ability to drive growth through strategic initiatives and product innovations. The balanced growth across both revenue and profitability metrics indicates a robust business model and effective management of market dynamics in the healthcare and consumer goods sectors.

Procter & Gamble Health Limited (P&G Health) has announced a significant leadership change in its finance department, with the resignation of its current Chief Financial Officer (CFO) and the appointment of a new executive to the role.

Lokesh Chandak's Departure

Mr. Lokesh Chandak, who has been serving as the Director & Chief Financial Officer of P&G Health, has tendered his resignation effective September 30, 2025. Chandak is set to transition to a new role within the broader P&G organization, taking on the position of Senior Director – Finance & Accounting for the Feminine Care division, overseeing Asia Pacific Enterprise Markets, Middle East, and Africa.

New CFO Appointment

The company has appointed Mr. Shashank Srowthy as the new Chief Financial Officer and Additional Executive Director, effective October 1, 2025. This appointment comes as part of P&G Health's strategic move to ensure a smooth transition in its financial leadership.

Shashank Srowthy's Profile

Mr. Srowthy brings a wealth of experience to his new role:

• Educational Background: Bachelor of Electronics & Telecommunication Engineering from Pune University and a Master of Management Studies from Jamnalal Bajaj Institute of Management Studies.
• Professional Experience: 14 years in various finance roles, with a significant tenure at P&G since 2011.
• Global Exposure: Has worked across multiple geographies, including India, Dubai, and Singapore, delivering notable results for various P&G businesses.

Appointment Details

The appointment of Mr. Srowthy as Executive Director is subject to several regulatory approvals:

• Approval from the Central Government, in accordance with Section 196 of the Companies Act, 2013.
• Shareholder approval at the ensuing Annual General Meeting.
• Allotment of Director Identification Number by the Ministry of Corporate Affairs.

Corporate Governance Compliance

P&G Health has confirmed that Mr. Srowthy meets all necessary qualifications for the role:

• Not debarred from holding directorship by any regulatory authority.
• Qualified to hold the office of Director under Section 164 of the Companies Act, 2013.
• Does not hold any shares in the company.
• Not related to any existing directors of the company.

Board Meeting Details

The Board of Directors of P&G Health convened a meeting on September 16, 2025, which lasted from 4:37 p.m. to 4:51 p.m., to approve these changes in leadership.

This leadership transition marks a significant moment for Procter & Gamble Health Limited as it moves forward with new financial stewardship. The company has expressed its appreciation for Mr. Chandak's contributions during his tenure and looks forward to Mr. Srowthy's leadership in driving financial strategy and growth.